Redeye comments on Cereno Scientific’s Q1 2023 report and the outcome of the rights issue. The company reports solid progress in the clinical phase IIa trial with CS1 in PAH. The net proceeds from Cereno Scientific’s recent rights issue are sufficient to primarily complete the clinical phase IIa trial and bring CS014 to the clinic. We make adjustments to our estimates and valuation.

Länk till analysen